SARomics Biostructures Board

  • sten Sorensen, SARomics Biostructures
  • Sten R. Sörensen, Chairman
    Currently also CEO at Cereno Scientific AB and Chairman of the Board at Stayble Therapeutics AB and AcuCort AB. Seasoned professional with international experience in a variety of sectors including Pharmaceutical, Biotechnology, Finance, Renewable Energy and Management Consulting. Assignments include senior global positions at AstraZeneca and Monsanto/GD Searle, CEO and Board member at Pharma Start Up Cortendo, Sector Head Life Science, Med Tech, Pharma & Private Equity at PwC, VP Bus Dev and Board Member at Eurowind.
    View Sten Sörensen’s LinkedIn profileView Sten Sörensen’s LinkedIn profile

  • Arvind Hundal, Board Director, SARomics Biostructures
  • Dr. Arvind M Hundal, Board Director
    Currently Senior Vice President of Business Development at the German company BioNTech and member of the Board of Directors at the Danish startup Bainan Biotech. Arvind has extensive experience of strategy, science, and finance within the international health care and life science industries. She has facilitated multiple financing rounds of both early startups and established pharma companies, including the Zealand Pharma IPO, securing a Series A of the AstraZeneca spin out Albireo and the acquisition of the Pfizer spinout Ziarco by Novartis.
    View Arvind's LinkedIn profileView Arvind's LinkedIn profile

  • Johan Kördel, SARomics Biostructures Board
  • Assoc. Prof. Johan Kördel, Board Director
    Senior Partner at Lundbeckfonden Ventures and board member of Acacia Pharma, BoneSupport, Enterome, Iconic Therapeutics, River Vision, VHsquared and Ziarco. He was previously co-founder and CEO of Sound Biotech ApS and co-founder and Senior Vice President of Research and Business Development of Biovitrum AB. Prior to these positions Johan worked a decade in the pharmaceutical company Pharmacia with management, research, early development, portfolio management, business development and alliance management. He is an associate professor in Physical Chemistry at Lund University, Sweden.
    View Johan Kördel’s LinkedIn profileView Johan Kördel’s LinkedIn profile

  • Dr. Charlotte Dyring, Board Director, SARomics Biostructures
  • Dr. Charlotte Dyring, Board Director
    Main co-founder of ExpreS2ion Biotechnologies ApS, a fully owned subsidiary of ExpreS2ion Biotech Holding AB, which was listed at Nasdaq First North in 2016. She was the main driver in the spin-out of the company from Affitech A/S in 2010, and followingly led the company as CEO. As board member of ExpreS2ion, she was an integral part of the successful IPO. Charlotte is presently owner and CEO of Caballus Biotech delivering consulting services to the life science industry and evaluations of European grant applications. Charlotte has more than 25 years of experience working in several scientific and managerial positions in the pharmaceutical and the biotechnology industry at Pharmacia & Upjohn AB, Pharmexa A/S and Affitech A/S. Besides management, she has an extensive track record in the field of protein expression in animal cells, upstream process development, and process transfer to cGMP manufacturing.
    View Charlotte's LinkedIn profileView Charlotte's LinkedIn profile

  • Jens Knobe, SARomiucs Biostructures Board
  • Jens Knobe, Board Director
    Senior Vice President Product & Market Development at Getinge Infection Control in the Getinge Group. Jens has 25 years of experience of driving growth in the life science and telecom industries.
    View Jens Knobe's LinkedIn profileView Jens Knobe's LinkedIn profile

  • Mikael Akke, SARomics Biostructures, CEO
  • Prof. Mikael Akke, Board Director
    Director NMR services and co-founder of SARomics Biostructures AB. Professor, Professor of Physical Chemistry at Lund University since 2005. He is an expert in biomolecular NMR spectroscopy. His current research includes fundamental studies of the driving forces underlying ligand binding.
    View Mikael's LinkedIn profileView Mikael's LinkedIn profile